Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

Articles

GOG-258 and PORTEC-3 Studies in Endometrial Cancer

January 4th 2021

GOG-249 Study in Early-Stage Endometrial Cancer

January 4th 2021

GOG 0209 Study in Advanced Endometrial Cancer

January 4th 2021

Role of Biomarker Testing in Endometrial Cancer

January 4th 2021

Risk Classification of Endometrial Cancer

January 4th 2021

Overview of Endometrial Cancer

January 4th 2021

Rapid Readouts: Phase III PAOLA-1/ENGOT-ov25 Trial

August 24th 2020

Dr. Monk on Emerging Therapies in Cervical Cancer

August 11th 2020

Bradley J. Monk, MD, FACS, FACOG, discusses emerging therapies in cervical cancer.

Dr. Monk on the Importance of Early Pap Testing in Cervical Cancer

July 27th 2020

Bradley J. Monk, MD, FACS, FACOG, discusses the importance of Pap testing early on in cervical cancer.

Dr. Monk on the Limitations of Current Treatment in Metastatic/Recurrent Cervical Cancer

July 24th 2020

Bradley J. Monk, MD, FACS, FACOG, discusses the limitations of current treatment options in metastatic or recurrent cervical cancer.

Novel Therapies: R2-GDP-GOTEL and Smart Start

July 17th 2020

Novel Treatment Combinations for R/R DLBCL

July 17th 2020

Relapsed/Refractory DLBCL: Unmet Needs

July 17th 2020

Emerging Treatments for Relapsed/Refractory DLBCL

July 17th 2020

SADAL Trial Regimen FDA Approval

July 17th 2020

SADAL Trial Overview

July 17th 2020

CAR T-Cell Therapy Clinical Trials

July 17th 2020

CAR T-Cell Therapy Response Rates

July 17th 2020

CAR T Cell Therapy in Relapsed/Refractory DLBCL

July 17th 2020

Relapsed/Refractory DLBCL Treatment Landscape

July 17th 2020